1
|
Guo J, Si G, Si F. Treg cells as a protective factor for Hashimoto`s thyroiditis: a Mendelian randomization study. Front Endocrinol (Lausanne) 2024; 15:1347695. [PMID: 38524638 PMCID: PMC10957564 DOI: 10.3389/fendo.2024.1347695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 02/26/2024] [Indexed: 03/26/2024] Open
Abstract
Background and objectives Hashimoto's thyroiditis (HT), a chronic autoimmune disorder impacting thyroid function, is a growing public health concern. The relationship between Treg cells and HT has been extensively studied, with Treg cells considered crucial in suppressing HT progression. However, these studies have mainly been observational, limiting our understanding of Treg cells' impact on HT risk. Leveraging large datasets, we utilized Mendelian randomization (MR) analysis to examine the causal association between Treg cell biomarkers and HT, providing additional validation for these relationships. Methods Comprehensive two-sample Mendelian randomization analysis was performed to determine the causal association between Treg cells signatures and HT in this study. Based on publicly available genetic data, we explored causal associations between 165 Treg cells signatures and HT risk. Results The European cohort study has identified five Treg cell phenotypes that causally protect against HT risk. Resting Treg %CD4 (OR = 0.975, 95% CI = 0.954~0.998, P = 0.030); CD4 on resting Treg (OR = 0.938, 95% CI = 0.882~0.997, P = 0.041; CD28- CD8dim %CD8dim (OR = 0.983, 95% CI = 0.969~0.998, P = 0.030); CD25 on CD39+ resting Treg (OR = 0.926, 95% CI = 0.864~0.991, P = 0.026); 5) CD28 on activated & secreting Treg (OR = 0.969, 95% CI = 0.942~0.996, P = 0.025). The Asian cohort study has identified four Treg cell phenotypes negatively correlated with the risk of HT. CD25hi %T cell (OR = 0.635, 95% CI = 0.473~852, P = 0.002); CD4 Treg %CD4 (OR = 0.829, 95% CI = 0.687~1.000, P = 0.050); CD127-CD8br %T cell (OR = 0.463, 95% CI =0.311~0.687, P< 0.001); CD3 on resting Treg (OR = 0.786, 95% CI = 0.621~0.994, P = 0.044). Conclusion Our study has demonstrated the close connection between Treg cells and HT by genetic means, thus providing foundational basis for future research.
Collapse
Affiliation(s)
- Jinzhou Guo
- Academy of Zhongjing, Henan University of Chinese Medicine, Zhengzhou, China
- Laboratory of Traditional Chinese Medicine (TCM) Syndrome and Prescription Signaling, Academy of Zhongjing, Zhengzhou, China
- Henan Key Laboratory of Traditional Chinese Medicine (TCM) Syndrome and Prescription Signaling, Henan International Joint, Zhengzhou, China
| | - Gao Si
- Department of Orthopedic, Peking University Third Hospital, Beijing, China
| | - Fuchun Si
- Academy of Zhongjing, Henan University of Chinese Medicine, Zhengzhou, China
- Laboratory of Traditional Chinese Medicine (TCM) Syndrome and Prescription Signaling, Academy of Zhongjing, Zhengzhou, China
- Henan Key Laboratory of Traditional Chinese Medicine (TCM) Syndrome and Prescription Signaling, Henan International Joint, Zhengzhou, China
| |
Collapse
|
2
|
Sumantri S, Hatta M, Natzir R, Rasyid H, Rengganis I, Massi MN, Islam AA, Lawrence G, Patellongi I, Benyamin AF. Metformin improves FOXP3 mRNA expression through suppression of interferon gamma levels in pristane-induced murine models of lupus. F1000Res 2021; 9:342. [PMID: 34386197 PMCID: PMC8327221 DOI: 10.12688/f1000research.23471.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/13/2021] [Indexed: 11/20/2022] Open
Abstract
Background: A recent study has indicated the potential of metformin therapy for lupus in animal models, but there has been no study evaluating the effect on pristane-induced lupus. This study aims to evaluate the effect of intraperitoneal versus oral metformin on interferon (IFN)-γ levels and FOXP3 mRNA expression on pristane-induced female BALB/c mice. Methods: In total, 31 female BALB/c mice, aged 6 weeks, were intraperitoneally induced with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane). After 120 days, the mice were grouped and treated with various treatments: normal saline 100 MCL, oral metformin 100mg/kg-BW, or intraperitoneal metformin 100mg/kg-BW. After 60 days of treatment, all treatment groups were sacrificed, and kidney specimens prepared and stained using hematoxylin and eosin. Results: IFNγ levels of saline controls vs. oral metformin group was 309.39 vs. 292.83 pg/mL (mean difference 16.56 pg/mL; 95% CI 0.74-32.37; p=0.042), and saline control vs. intraperitoneal metformin group was 309.39 vs. 266.90 pg/mL (mean difference 42.49 pg/mL; 95% CI 29.24-55.73 pg/mL; p<0.001). FOXP3 mRNA expression changes in saline controls vs. oral metformin group was 6.90 vs. 7.79-fold change (mean difference -0.89-fold change; 95% CI -1.68-(-0.11); p=0.03) and in saline controls vs. intraperitoneal metformin group was 6.90 vs. 9.02-fold change (mean difference -2.12-fold change; 95% CI -2.99-(-1.25); p=<0.001). Correlation analysis of FOXP3 mRNA expression and IFNγ level changes revealed a Pearson correlation of -0.785 (p=0.001) and R2 value of 0.616 (p=0.001). Conclusion: Metformin is a potential new therapy to reduce the levels of IFNγ and increase FOXP3 mRNA expression in mice models of systemic lupus erythematosus.
Collapse
Affiliation(s)
- Stevent Sumantri
- Department of Internal Medicine, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia
| | - Mochammad Hatta
- Department of Microbiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Rosdiana Natzir
- Department of Biochemistry, Universitas Hasnuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Haerani Rasyid
- Department of Internal Medicine, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Iris Rengganis
- Department of Internal Medicine, Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia
| | - Muhammad Nasrum Massi
- Department of Microbiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Andi Asadul Islam
- Department of Surgery, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Gatot Lawrence
- Department of Pathological Anatomy, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Ilhamjaya Patellongi
- Department of Physiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | | |
Collapse
|
3
|
Moore E, Putterman C. Are lupus animal models useful for understanding and developing new therapies for human SLE? J Autoimmun 2020; 112:102490. [PMID: 32535128 DOI: 10.1016/j.jaut.2020.102490] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 05/18/2020] [Indexed: 01/13/2023]
Abstract
Systemic lupus erythematosus is a systemic autoimmune disease driven by a complex combination of genetic, environmental, and other immunoregulatory factors. The development of targeted therapies is complicated by heterogeneous clinical manifestations, varying organ involvement, and toxicity. Despite advances in understanding the mechanisms contributing to SLE, only one biologic drug, belimumab, is FDA-approved. The identification and development of potential therapies have largely been driven by studies in lupus animal models. Therefore, direct comparison of both the therapeutic and immunological findings in human and murine SLE studies is critical and can reveal important insights into indeed how useful and relevant are murine studies in SLE drug development. Studies involving belimumab, mycophenolate mofetil, abatacept, rituximab, and anti-interferon strategies generally demonstrated analogous findings in the attenuation of SLE manifestations and modulation of select immune cell populations in human and murine SLE. While further basic and translational studies are needed to identify SLE patient subsets likely to respond to particular therapeutic modalities and in dissecting complex mechanisms, we believe that despite some inherent weaknesses SLE mouse models will continue to be integral in developing targeted SLE therapies.
Collapse
Affiliation(s)
- Erica Moore
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Chaim Putterman
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA; Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA; Bar-Ilan University Azrieli Faculty of Medicine, Safed, Israel; Research Institute, Galilee Medical Center, Nahariya, Israel.
| |
Collapse
|
4
|
Sumantri S, Hatta M, Natzir R, Rasyid H, Rengganis I, Massi MN, Islam AA, Lawrence G, Patellongi I, Benyamin AF. Metformin improves FOXP3 mRNA expression through suppression of interferon gamma levels in pristane-induced murine models of lupus. F1000Res 2020; 9:342. [PMID: 34386197 PMCID: PMC8327221 DOI: 10.12688/f1000research.23471.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/13/2021] [Indexed: 10/18/2023] Open
Abstract
Background: A recent study has indicated the potential of metformin therapy for lupus in animal models, but there has been no study evaluating the effect on pristane-induced lupus. This study aims to evaluate the effect of intraperitoneal versus oral metformin on interferon (IFN)-γ levels and FOXP3 mRNA expression on pristane-induced female BALB/c mice. Methods: In total, 31 female BALB/c mice, aged 6 weeks, were intraperitoneally induced with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane). After 120 days, the mice were grouped and treated with various treatments: normal saline 100 MCL, oral metformin 100mg/kg-BW, or intraperitoneal metformin 100mg/kg-BW. After 60 days of treatment, all treatment groups were sacrificed, and kidney specimens prepared and stained using hematoxylin and eosin. Results: IFNγ levels of saline controls vs. oral metformin group was 309.39 vs. 292.83 pg/mL (mean difference 16.56 pg/mL; 95% CI 0.74-32.37; p=0.042), and saline control vs. intraperitoneal metformin group was 309.39 vs. 266.90 pg/mL (mean difference 42.49 pg/mL; 95% CI 29.24-55.73 pg/mL; p<0.001). FOXP3 mRNA expression changes in saline controls vs. oral metformin group was 6.90 vs. 7.79-fold change (mean difference -0.89-fold change; 95% CI -1.68-(-0.11); p=0.03) and in saline controls vs. intraperitoneal metformin group was 6.90 vs. 9.02-fold change (mean difference -2.12-fold change; 95% CI -2.99-(-1.25); p=<0.001). Correlation analysis of FOXP3 mRNA expression and IFNγ level changes revealed a Pearson correlation of -0.785 (p=0.001) and R2 value of 0.616 (p=0.001). Conclusion: Metformin is a potential new therapy to reduce the levels of IFNγ and increase FOXP3 mRNA expression in mice models of systemic lupus erythematosus.
Collapse
Affiliation(s)
- Stevent Sumantri
- Department of Internal Medicine, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia
| | - Mochammad Hatta
- Department of Microbiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Rosdiana Natzir
- Department of Biochemistry, Universitas Hasnuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Haerani Rasyid
- Department of Internal Medicine, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Iris Rengganis
- Department of Internal Medicine, Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia
| | - Muhammad Nasrum Massi
- Department of Microbiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Andi Asadul Islam
- Department of Surgery, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Gatot Lawrence
- Department of Pathological Anatomy, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | - Ilhamjaya Patellongi
- Department of Physiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia
| | | |
Collapse
|
5
|
Xia S, Chen Q, Niu B. CD28: A New Drug Target for Immune Disease. Curr Drug Targets 2019; 21:589-598. [PMID: 31729942 DOI: 10.2174/1389450120666191114102830] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/22/2019] [Accepted: 11/04/2019] [Indexed: 01/05/2023]
Abstract
BACKGROUND CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. CTLA-4 has sequence homology to CD28, and is expressed on T cells after activation. It provides an inhibition signal coordinated with CD28 to regulate T cell activation. Both of them regulate T cell proliferation and differentiation and play an important role in the immune response pathway in vivo. OBJECTIVE We studied the special role of different structural sites of CD28 in producing costimulatory signals. METHODS We reviewed the relevant literature, mainly regarding the structure of CD28 to clarify its biological function, and its role in the immune response. RESULTS In recent years, increasingly attention has been paid to CD28, which is considered as a key therapeutic target for many modern diseases, especially some immune diseases. CONCLUSION In this paper, we mainly introduce the structure of CD28 and its related biological functions, as well as the application of costimulatory pathways targeting CD28 in disease treatment.
Collapse
Affiliation(s)
- Sijing Xia
- College of Life Science, Shanghai University, Shanghai, China
| | - Qin Chen
- College of Life Science, Shanghai University, Shanghai, China
| | - Bing Niu
- College of Life Science, Shanghai University, Shanghai, China
| |
Collapse
|
6
|
Abstract
A resurgence in the development of newer gene therapy systems has led to recent successes in the treatment of B cell cancers, retinal degeneration and neuromuscular atrophy. Gene therapy offers the ability to treat the patient at the root cause of their malady by restoring normal gene function and arresting the pathological progression of their genetic disease. The current standard of care for most genetic diseases is based upon the symptomatic treatment with polypharmacy while minimizing any potential adverse effects attributed to the off-target and drug-drug interactions on the target or other organs. In the kidney, however, the development of gene therapy modifications to specific renal cells has lagged far behind those in other organ systems. Some positive strides in the past few years provide continued enthusiasm to invest the time and effort in the development of new gene therapy vectors for medical intervention to treat kidney diseases. This mini-review will systematically describe the pros and cons of the most commonly tested gene therapy vector systems derived from adenovirus, retrovirus, and adeno-associated virus and provide insight about their potential utility as a therapy for various types of genetic diseases in the kidney.
Collapse
Affiliation(s)
- Lori Davis
- College of Pharmacy, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Frank Park
- College of Pharmacy, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee
| |
Collapse
|
7
|
Correa Freitas E, Evelyn Karnopp T, de Souza Silva JM, Cavalheiro do Espírito Santo R, da Rosa TH, de Oliveira MS, da Costa Gonçalves F, de Oliveira FH, Guilherme Schaefer P, André Monticielo O. Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. Autoimmunity 2019; 52:69-77. [PMID: 31088305 DOI: 10.1080/08916934.2019.1613383] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Systemic lupus erythematosus (SLE) is a multifactorial and autoimmune inflammatory disease with pleomorphic clinical manifestations involving different organs and tissues. The study of different murine models has provided a better understanding of these autoimmune phenomena. Pristane-induced lupus represents a suitable model to study factors that could influence the induction and/or progression of SLE, including genetic factors. The objective of the present study was to evaluate the development and evolution of SLE after vitamin D supplementation in PIL model. Here, we evaluated the effects of vitamin D supplementation in model of pristane-induced SLE in female BALB/c mice. The animals were randomly divided into three groups: control group (CO), pristane-induced lupus group (PIL) and pristane-induced lupus group plus vitamin D (VD). Lupus was induced in PIL and VD groups using pristane. PIL group showed arthritis and kidney injury, characterized by increased proteinuria, glomerular mesangial expansion and inflammation. Moreover, PIL model showed increased levels of IL-6, TNF-α and IFN-γ in serum. We observed that treatment with vitamin D improved arthritis through reduced of incidence and arthritis clinical score and edema, but does not influenced renal injury. Treatment with vitamin D was not able to reduce proteinuria levels, decrease mesangial hypercellularity or IgG and IgM deposition in the kidney. Vitamin D supplementation did not alter IL-6, TNF-α, IL-2 and IL-4, but reduce IFN-γ. These results support that the role of vitamin D may be different depending on acting site, what could explain different responses according clinical phenotype. Therefore, further investigations of vitamin D are needed to explore the supplement dosage, timing, and the molecular basis in SLE.
Collapse
Affiliation(s)
- Eduarda Correa Freitas
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,b Post-Graduate Program in Medical Sciences , School of Medicine, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Thaís Evelyn Karnopp
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,b Post-Graduate Program in Medical Sciences , School of Medicine, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Jordana Miranda de Souza Silva
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,b Post-Graduate Program in Medical Sciences , School of Medicine, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Rafaela Cavalheiro do Espírito Santo
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,b Post-Graduate Program in Medical Sciences , School of Medicine, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Thales Hein da Rosa
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Mayara Souza de Oliveira
- d Post-Graduate Program in Medical Sciences: Endocrinology , School of Medicine, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Fabiany da Costa Gonçalves
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil
| | - Francine Hehn de Oliveira
- e Department of Surgical Pathology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Pedro Guilherme Schaefer
- e Department of Surgical Pathology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| | - Odirlei André Monticielo
- a Laboratory of Autoimmune Diseases, Division of Rheumatology , Hospital de Clínicas de Porto Alegre , Porto Alegre , Brazil.,c Department of Internal Medicine, Division of Rheumatology , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil
| |
Collapse
|
8
|
Novelli R, Benigni A, Remuzzi G. The role of B7-1 in proteinuria of glomerular origin. Nat Rev Nephrol 2018; 14:589-596. [DOI: 10.1038/s41581-018-0037-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
Abstract
PURPOSE OF REVIEW The complexity and heterogeneity of the clinical presentation in systemic lupus of erythematosus (SLE), combined to the inherent limitations of clinical research, have made it difficult to investigate the cause of this disease directly in patients. Various mouse models have been developed to dissect the cellular and genetic mechanisms of SLE, as well as to identify therapeutic targets and to screen treatments. The purpose of this review is to summarize the major spontaneous and induced mouse models of SLE and to provide an update on the major advances they have contributed to the field. RECENT FINDINGS Mouse models of SLE have continued to contribute to understand the cellular, signaling and metabolic mechanisms contributing to the disease and how targeting these pathways can provide therapeutic targets. Whenever possible, we discuss the advantage of using one model over the others to test a specific hypothesis. SUMMARY Spontaneous and induced models of lupus models are useful tools for the study of the cause of the disease, identify therapeutic targets and screen treatments in preclinical studies. Each model shares specific subsets of attributes with the disease observed in humans, which provides investigators a tool to tailor to their specific needs.
Collapse
|
10
|
dos Santos M, Favero G, Bonomini F, Stacchiotti A, Rodella LF, Veronese FV, Rezzani R. Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. Life Sci 2018; 193:242-251. [DOI: 10.1016/j.lfs.2017.10.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Revised: 10/23/2017] [Accepted: 10/27/2017] [Indexed: 12/11/2022]
|
11
|
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G. Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. Nephron Clin Pract 2016; 133:129-38. [PMID: 27198457 DOI: 10.1159/000446324] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 04/06/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Lupus nephritis (LN) is a frequent complication and a major predictor of poor prognosis of systemic lupus erythematosus. Immune complex deposition and T cell infiltration are crucial events in LN pathogenesis. B7-1 (CD80), normally expressed by antigen-presenting cells, is one of the major co-stimulators of T-cell activation through the binding with its counter-receptors CD28 and cytotoxic T-lymphocyte antigen-4. Unexpectedly, B7-1 induction was described at the podocyte level in patients affected by different renal diseases, including LN. These observations suggested a novel exciting function for B7-1 as a biomarker of podocyte injury, and hence that B7-1 inhibitory drugs could serve as podocyte-targeted treatment of intractable renal diseases. However, subsequent studies hardly questioned the reliability of B7-1 detection assays and the therapeutic efficacy of B7-1 blockade in proteinuric patients, casting doubts on B7-1 expression by podocytes. Here, we thoroughly investigated whether B7-1 was indeed expressed by podocytes in LN, before even considering employing B7-1 blockade in patients with severe manifestations of LN and unfavourable prognosis. METHODS Applying different immunohistochemical assays with 4 primary antibodies, we analysed kidney biopsies from 42 LN patients at different stages of the disease, and from NZB/NZW mice, an LN model. RESULTS B7-1 was not induced in podocytes in human and murine LN; instead its expression was confined to infiltrating inflammatory cells. CONCLUSION B7-1 is not expressed by podocytes in LN. A renoprotective effect of B7-1 blockade in LN patients cannot be ruled out but, if confirmed, cannot be the result of an effect on podocyte B7-1.
Collapse
Affiliation(s)
- Rubina Novelli
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy
| | | | | | | | | |
Collapse
|
12
|
Ma L, Shen X, Gao Y, Wu Q, Ji M, Luo C, Zhang M, Wang T, Chen X, Tao L. Blocking B7-1/CD28 Pathway Diminished Long-Range Brain Damage by Regulating the Immune and Inflammatory Responses in a Mouse Model of Intracerebral Hemorrhage. Neurochem Res 2016; 41:1673-83. [PMID: 26980009 DOI: 10.1007/s11064-016-1883-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Revised: 02/28/2016] [Accepted: 03/02/2016] [Indexed: 01/21/2023]
Abstract
Acute brain injuries can activate bidirectional crosstalk between the injured brain and the immune system. The immune system, particularly T lymphocytes and cytokines, has been implicated in the progression of brain injury after intracerebral hemorrhage (ICH). Co-stimulatory molecules B7-1 (CD80)/B7-2 (CD86) binding cognate receptor provides a secondary signaling to T cell activation. The aim of our study was to explore the effects of anti-B7-1 antibody on the development and prognosis of cerebral hemorrhage and to investigate the possible underlying mechanism. Mice were inner canthus veniplex administered with anti-B7-1 antibody at 10 min and 24 h after ICH and sacrificed on the third day after ICH. Immune function was assessed via splenocyte proliferation assay and organism index, respectively. IFN-γ and IL-4 were detected by enzyme-linked immuno sorbent assay. The cerebral edema was evaluated via brain water content. The levels of autophagy and apoptosis related proteins were measured by western blotting analysis. In addition, functional outcome was studied with pole-climbing test and morris water maze. The mice were weighed on 0, 1, 3, 14 and 21 days after ICH. The treatment with anti-B7-1 antibody significantly lowered immune function, and reduced the latency of water maze on 18 and 20 days, the ratio of IFN-γ/IL-4 as well as body weight on day 3 after cerebral hemorrhage. Our study suggests that in the cerebral hemorrhage mice brain anti-B7-1 antibody may reduce long-range brain damage by reversing immune imbalance.
Collapse
Affiliation(s)
- Lu Ma
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Xi Shen
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Yuan Gao
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Qiong Wu
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Mengmeng Ji
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Chengliang Luo
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Mingyang Zhang
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Tao Wang
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Xiping Chen
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China
| | - Luyang Tao
- Department of Forensic Medicine, Medical School of Soochow University, No. 178, Ganjiang East Road, Soochow, 215123, China.
| |
Collapse
|